Medicare expands IVIG coverage to rare neurological conditions
H.R. 1143 — Medicare IVIG Access Enhancement Act of 2025 · Filed by Adrian Smith (R-NE) · 2 cosponsors · Introduced Feb 7, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill expands Medicare coverage for in-home intravenous immune globulin (IVIG) treatment to include two additional neurological conditions—chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy (MMN)—beginning January 1, 2027. Currently, Medicare covers in-home IVIG only for primary immune deficiency diseases; this bill adds CIDP and MMN to that list and allows the Secretary of Health and Human Services to set different payment rates for the new conditions.
Why we flagged it
The bill's sole operative mechanism is to expand the list of diagnoses eligible for an existing Medicare benefit (in-home IVIG administration). It is a straightforward coverage-expansion measure with no hidden provisions or narrow carve-outs.
What the text implies
- The January 1, 2027 effective date creates a 2-year lag between enactment and coverage, potentially delaying patient access despite legislative approval.
- Section 1842(o)(8) amendment grants the Secretary discretion to set different payment rates for CIDP/MMN versus primary immune deficiency disease IVIG, which could result in lower reimbursement for the new conditions and affect provider willingness to offer the service.
The full analysis lists 3 implications of this text.
Who stands to gain
IVIG manufacturers and distributors; Home infusion therapy providers; Specialty pharmacy networks